Company Filing History:
2 out of 3,539 
2 out of 785 
Years Active: 2007-2011
Title: Oral Alpan: Innovator in Hemophilia Treatment
Introduction
Oral Alpan is a notable inventor based in Rockville, MD (US), recognized for his contributions to the field of hemophilia treatment. He holds 2 patents that focus on innovative methods for managing antigen-deficiency diseases, particularly hemophilia A and B.
Latest Patents
Alpan's latest patents include methods for the induction of tolerance through oral administration of factor VIII and the treatment of hemophilia. The first patent discloses a simple method for treating antigen-deficiency diseases by orally administering a therapeutically effective amount of the deficient antigen, which is not present in a liposome. This method aims to enhance hemostasis in individuals with hemophilia A or B by providing the necessary clotting factor to induce oral tolerance. The second patent reiterates this approach, emphasizing the importance of delivering the appropriate clotting factor orally to improve patient outcomes.
Career Highlights
Throughout his career, Oral Alpan has worked with esteemed organizations such as the National Institutes of Health, a component of the US Department of Health & Human Services, and Virginia Tech Intellectual Properties, Inc. His work in these institutions has significantly contributed to advancements in medical research and treatment methodologies.
Collaborations
Alpan has collaborated with notable colleagues, including Tirumalai Kamala and Polly Matzinger, who have also made significant contributions to the field of immunology and related research.
Conclusion
Oral Alpan's innovative approaches to treating hemophilia through oral administration of clotting factors represent a significant advancement in medical science. His patents and career achievements highlight his dedication to improving the lives of individuals with antigen-deficiency diseases.